Insilico Medicine

Insilico Medicine is a biotechnology company focused on leveraging generative AI and automation to enhance longevity and sustainability. The company aims to revolutionize drug discovery and development processes through advanced technology.

Insilico Medicine primarily serves pharmaceutical companies, research institutions, and healthcare organizations seeking to innovate in drug development and aging research. Their AI solutions are designed for entities focused on longevity and sustainability.

Insilico Medicine was founded in 2014. Since its inception, the company has focused on integrating AI technologies into the drug discovery process.

Insilico Medicine was founded by Alex Zhavoronkov, Ph.D., who has been instrumental in leading the company's vision and strategy since its establishment.

Insilico Medicine is best known for its innovative use of generative AI in drug discovery and development, particularly in the context of aging research. Their platforms, such as Pharma.ai and PandaOmics, are widely recognized in the industry.